Loading clinical trials...

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) | Clinical Trials | Clareo Health

WITHDRAWNPHASE3

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

Comparison of Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B at Birth Dose Using New Hepatitis B Bulk (Bio Farma), in Indonesian Infants

NCT05482282•PT Bio Farma

View on ClinicalTrials.gov

Summary

This bridging study is a randomized, double-blind, two arms parallel group, prospective intervention study. The primary objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma).

Detailed Description

This bridging study is a randomized, double blind, two arms parallel groups, prospective intervention study. Total 220 infants, 0-3 days old will be involved in this study. The subject will be divided into 2 groups, 110 subjects are the investigational group and 110 subjects are the active comparator group. The objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma) and to asses the safety of DTP-HB-Hib Vaccine (Bio Farma) and Recombinant Hepatitis B Vaccine using new Hepatitis B bulk (Bio Farma).

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Healthy, full term, newborns infants.
•2. Infant born after 37-42 weeks of pregnancy.
•3. Infant weighing 2500 gram or more at birth.
•4. Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form.
•5. Parents will commit themselves to comply with the indications of the investigator and with the schedule of the trial.

Exclusion Criteria

•1. Child concomitantly enrolled or scheduled to be enrolled in another trial.
•2. Child evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature 37.5 celcius degrees on Day 0).
•3. Child suspected of allergy to any component of the vaccines (e.g. formaldehyde), based on anamnesis.
•4. Child suspected of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection, based on anamnesis
•5. Newborn suspected of congenital or acquired immunodeficiency, based on anamnesis
•6. Child received or plans to receive any treatment likely to alter the immune response intravenous (immunoglobulins, blood-derived products or long term corticotherapy (\> 2 weeks)).
•7. Child received other vaccination with the exception of BCG and poliomyelitis.
•8. Child has any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
•9. Mother with HbsAg and HIV positive (by rapid test within 30 days prior subject's birth)
•10. Mother suspected of immunodeficiency disease based on anamnesis

Locations (3)

Garuda Primary Health Centre

Bandung, West Java, Indonesia

Ibrahim Adjie Primary Health Centre

Bandung, West Java, Indonesia

Puter Primary Health Centre

Bandung, West Java, Indonesia

Key Dates

Start Date

December 1, 2025

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

June 5, 2025

Conditions

Diphtheria Vaccine Adverse ReactionTetanus Vaccine Adverse ReactionPertussis Vaccine Adverse ReactionHaemophilus Influenzae Type B Vaccine Adverse ReactionHepatitis B Vaccine Adverse Reaction

Interventions

Recombinant Hepatitis B new Bulk vaccine

BIOLOGICAL

DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine

BIOLOGICAL

Recombinant Hepatitis B vaccine (Registered BioFarma)

BIOLOGICAL

Pentabio

BIOLOGICAL